[Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease]. [PDF]
Wang XY, Sun HM, Gao YH.
europepmc +1 more source
[Factors influencing hemorrhagic transformation after mechanical thrombectomy in patients with acute ischemic stroke patients]. [PDF]
Feng F +6 more
europepmc +1 more source
[Research advances on hepatocyte zonal changes in metabolic associated fatty liver disease]. [PDF]
Li Y, Huang ZW, Gan JT, Zhang QF, Fu WW.
europepmc +1 more source
[Research progress on the regulatory role and mechanisms of the Hippo signaling pathway in the pathogenesis of congenital heart disease]. [PDF]
Li QX, Chen JY, Zhu YB, Li HB.
europepmc +1 more source
[Research progress on the role and mechanism of magnesium element and magnesium materials in tendon-bone interface healing]. [PDF]
Yue H +6 more
europepmc +1 more source
[Novel targets and drugs for the treatment of portal hypertension in liver cirrhosis]. [PDF]
Zhu CP, Xie WF.
europepmc +1 more source
[Alcohol liver disease: immunoregulatory mechanisms and precision therapeutic targets]. [PDF]
Shen HY, Wei LM, Zuo L, Wang H.
europepmc +1 more source
[Emphasis on the etiological diagnosis and management of non-cirrhotic portal hypertension]. [PDF]
Liu J, Zhao LL, Li J.
europepmc +1 more source
[LGALS3 is an efferocytosis-related biomarker and potential traditional Chinese medicine therapeutic target for diabetic kidney disease complicated with heart failure]. [PDF]
Hu D +6 more
europepmc +1 more source

